evenfolio

Healthcare · NSE: ERIS

Eris Lifesciences

Q2 FY27 earnings highlights, from the results presentation

Price as of 16 Nov 2026
1,329.70+1.72%

Q2 FY27 · From the investor presentation

Read the filing on NSEFiling

100​bpsGross margin improvement · Domestic Branded Formulations · going forwardSlides · p. 5
₹220​CrCapex · H1 FY27Slides · p. 13
75.7​%DBF gross margin · Domestic Branded Formulations · Q2 FY27Slides · p. 6
M.Cap
₹18,427Cr
P/E
26.0×
1Y return
−14.24%
From 52W high
−23.6%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue892792+12.6%873+2.2%
EBITDA309288+7.3%296+4.4%
EBITDA margin34.7%36.4%-170 bps33.9%+75 bps
One-off items-36————
PBTProfit before tax157172-9.0%180-12.8%
Net profit184120+52.9%142+29.0%
EPS (₹)13.258.81+50.4%10.26+29.1%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

Guidance

Gross margin · Domestic Branded Formulations · long term100 bpsEx-Zorvia, about 100 bps gross margin improvement expected going forward

Domestic Branded Formulations: DBF EBITDA slightly ahead of guidance in Q2

Slides · p. 5
“DBF EBIDTA slightly ahead of guidance in Q2”

Domestic Branded Formulations: Further gross margin gain expected from portfolio out-licensed to Zorvia

Slides · p. 6
“Further gross margin gain expected from the out-licensed portfolio”

In short

  1. 01Q2 FY27 consolidated revenue grew 12.6% and PAT grew 39.2%.
  2. 02Q2 EBITDA was Rs 309 cr at a 34.7% margin, up 7.3%.
  3. 03DBF revenue grew 14.1%; ex-Zorvia DBF growth was 16.5%.
  4. 04Ex-Zorvia, about 100 bps DBF gross margin improvement is expected going forward.
  5. 05A Rs ~36 cr receivables write-off was booked; the NCLT merger order gave a Rs 65 cr tax benefit.
  6. 06Capex cycle is winding down; Swiss Unit III PV batches expected by Apr 27.
  7. 07Net debt fell by about Rs 111 cr in H1.

Capex

Swiss Parenterals: Swiss new Unit III construction on track; PV batches by Apr 27

Slides · p. 11
“• Construction on track; PV batches by Apr 27”

Capex cycle winding down by end of FY27

Slides · p. 14
“Capex cycle is winding down by end of as % of Revenue 23.3% 20.7% 22.2% 21.2% FY27”

Eris Bionxt, Swiss and Levim investments yet to contribute; returns expected from next year

Slides · p. 14
“Three major capital investments - Eris EBITDA Margin 34.7% 36.4% 34.3% 36.1% Bionxt, Swiss and Levim - are yet to Depreciation 17 12 36.8% 32 26 21.2% Amortisation 57 57 - 113 113 - contribute; returns expected from next Finance Cost 46 50 -6.3% 93 98 -5.3% year”

Capacity

Bhopal facility commercialized; vials and cartridges in production

Slides · p. 6
“Bhopal facility commercialized Gain Vials and Cartridges now in production”

Full manufacturing shift to Bhopal expected in second half of next year

Slides · p. 6
“Complete shift expected in the second half of next year”

Swiss Parenterals: Unit III lines planned: PFS, vials, lyophilized and cartridges

Slides · p. 11
“• Lines planned: PFS, Vials, Lyophilized and Cartridges (incl. Dual Chamber)”

Segments

Domestic Branded Formulations: Ex-Zorvia, Q2 DBF growth is 16.5%

Slides · p. 5
“• Ex-Zorvia, Q2 DBF growth is 16.5%”

Ex-Zorvia Eris growth is 17%

Slides · p. 7
“Ex-Zorvia Eris growth is 17%.”

Diabetes: Diabetes emerged stronger after insulin and semaglutide launches

Slides · p. 8
“Diabetes has emerged stronger after Insulins and Semaglutide launches We also have the strongest pipeline of products going ahead in diabetes”

Swiss Parenterals: Swiss top 10 countries contribute 50%+ of export revenues

Slides · p. 11
“Base Business Top 10 countries Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Business intact, steady and protected Contribute 50% + of export revenues”

Domestic Branded Formulations: 86% of portfolio chronic and sub-chronic; top 10 brands 44% of sales

Slides · p. 4
“86% portfolio is Chronic and Sub-chronic with Top 10 brands contributing to 44% of Sales”

Demand

All major therapies outgrew the market in Q2

Slides · p. 7
“All major therapies in Q2 have outgrown the market”

Swiss Parenterals: Swiss CDMO pipeline: current opportunities intact

Slides · p. 11
“Current opportunities intact; no”

Margins and costs

Domestic Branded Formulations: DBF EBITDA margin fell 191 bps in Q2 to 35.7% and 217 bps in H1 to 35.2%

Slides · p. 5
“EBITDA margin: 37.6% → 35.7% -191 bps EBITDA margin: 37.4% → 35.2% -217 bps”

Domestic Branded Formulations: DBF other expenses rose 29.8% in Q2 to Rs 187 cr

Slides · p. 9
“Other Expenses 187 144 29.8% 357 287 24.6%”

Debt and working capital

Domestic Branded Formulations: DBF debtor days at 61 in Sep FY27

Slides · p. 9
“DBF Debtor days at 61 in Sep’ FY27”

H1 operating cash flow was 105% of EBITDA

Slides · p. 13
“H1 OCF = 105% of EBIDTA”

Net debt reduced by about Rs 111 cr in H1

Slides · p. 14
“Net Debt reduction of ~111 cr in H1”

Consolidated debtor days at 70 in Sep FY27

Slides · p. 14
“Consol Debtor days at 70 in Sep’ FY27”

Acquisitions and new business

Domestic Branded Formulations: Injectables licensed to Zorvia Healthcare; Eris keeps brands and earns 7% royalty

Slides · p. 5
“to Zorvia Healthcare; Eris retains brand ownership and earns a 7% royalty”

Domestic Branded Formulations: Brands licensed to Zorvia contribute about Rs 100 cr of sales

Slides · p. 5
“~₹100 cr of sales”

Diabetes: Nod to conduct Phase 1 and Phase 3 trials for India's first recombinant semaglutide

Slides · p. 8
“• Received the nod to conduct Phase 1 and 37.3% Phase 3 trials for India’s first Recombinant 18.5% Semaglutide”

Diabetes: Three more analogs to enter regulatory pathway from Dec-Mar this financial year

3​analogs
Slides · p. 8
“• Three more analogs going in the regulatory pathway from Dec-Mar this financial year”

NCLT order received for merger of subsidiaries Aprica, Eris Oaknet and ETL

Slides · p. 9
“Company has received NCLT order Depreciation 14 10 37.9% 28 20 37.6% for merger between its subsidiaries Amortisation 57 57 - 113 113 - Aprica, Eris Oaknet and ETL.”

One-offs

Domestic Branded Formulations: Receivables write-off of about Rs 36 cr, of at-risk products only

Slides · p. 9
“*Receivables write-off of Rs. ~36 cr as % of Revenue 23.1% 20.3% 22.2% 20.3% of at-risk products only”

Positive tax impact of Rs 65 cr due to NCLT order

Slides · p. 9
“has a positive tax impact of Rs. 65 cr Other Income 2 1 - 5 2 - due to the NCLT order”

Risks

Swiss Parenterals: Swiss base business largely uninterrupted; EU CAPA actions underway

Slides · p. 11
“Base business largely uninterrupted; EU CAPA actions underway”

Swiss Parenterals: EU CAPA execution on track; shutdown planned

Slides · p. 11
“Execution on track; shutdown planned”

Swiss Parenterals: Swiss EU CAPA shutdown planned in Q3; no CDMO pipeline cancellations

Slides · p. 11
“Execution on track; shutdown planned Current opportunities intact; no in Q3 cancellations”

Other

Domestic Branded Formulations: DBF revenue grew 14.1% YoY in Q2 FY27 with 35.7% EBITDA margin

Slides · p. 5
“Revenue grew 14.1% YoY in Q2 FY27 with EBITDA margin of 35.7%”

Q2 consolidated revenue grew 12.6% and PAT grew 39.2%

Slides · p. 13
“Q2 revenue growth of 12.6% with a PAT growth of 39.2%”

Q2 EBITDA Rs 309 cr, 34.7% margin, up 7.3% YoY

Slides · p. 13
“Q2 EBIDTA = Rs. 309 cr. – 34.7% EBIDTA margin and 7.3% growth yoy”

Q2 PAT Rs 187 cr, up 39.2%; adjusted PAT Rs 158 cr, up 17.5%

Slides · p. 13
“• Q2 PAT = Rs. 187 cr. – up 39.2% yoy; Adjusted PAT of Rs. 158 cr. – up • H1 Effective Tax Rate = 20.4% 17.5% yoy”

H1 effective tax rate 20.4%

Slides · p. 13
“H1 Effective Tax Rate = 20.4%”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools